View More Recent Stories

Aug 30, 2022 06:00AM Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated
Aug 4, 2022 04:01PM Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
Dec 13, 2021 05:04AM Sangamo Therapeutics (SGMO) and Pfizer (PFE) Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Dec 12, 2021 04:30PM Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Dec 7, 2020 07:01AM Pfizer (PFE), Sangamo (SGMO) Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy
Dec 7, 2020 07:00AM Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10¹³ VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy
Oct 7, 2020 06:48AM Pfizer (PFE), Sangamo Therapeutics Inc. (SGMO) Report First Participant Dosing in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment
Oct 7, 2020 06:45AM Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment
Jun 18, 2020 09:05AM Pfizer (PFE), Sangamo (SGMO) Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelp
Jun 18, 2020 09:00AM Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (S
Jun 18, 2020 09:00AM Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (S
Apr 21, 2020 07:05AM Sangamo Therapeutics (SGMO), Mogrify announce collaboration and exclusive license agreement for Mogrify's iPSC- and ESC-derived regulatory T cells
Apr 21, 2020 07:00AM Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells
Feb 27, 2020 04:38PM Sangamo Therapeutics (SGMO), Biogen (BIIB) Enter Gene Regulation Therapies Collaboration
Feb 27, 2020 04:06PM Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
Feb 27, 2020 04:06PM Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
Feb 27, 2020 04:06PM Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
Dec 9, 2019 06:14AM Sangamo Therapeutics (SGMO), Pfizer (PFE) Report Updated Follow-Up Results from Phase 1/2 Alta Study Evaluating Investigational SB-525 Gene Therapy
Dec 7, 2019 09:00AM Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment
Jul 8, 2019 05:50AM Sangamo Therapeutics (SGMO), Pfizer (PFE) Report Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy
Jul 5, 2019 11:15PM Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels
Apr 2, 2019 07:01AM Sangamo Therapeutics (SGMO), Pfizer (PFE) Report Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy
Apr 2, 2019 07:00AM Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy
Apr 2, 2019 07:00AM Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy
May 16, 2018 07:32AM Sangamo Therapeutics (SGMO) & Sanofi (SNY) Company, Bioverativ Inc., Report FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease
May 16, 2018 07:30AM Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease
Apr 25, 2018 09:13AM Pre-Open Movers 04/25: (VICR) (TZOO) (CREE) Higher; (TRVG) (TER) (EW) Lower (more...)
Jan 3, 2018 07:32AM Sangamo Therapeutics (SGMO) and Pfizer (PFE) Announced Collaboration for ALS Treatments; $12M Upfront
Jan 3, 2018 07:31AM Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS
Oct 2, 2017 07:35AM Sangamo Biosciences (SGMO) & Bioverativ Reports FDA Acceptance Of IND Application For ST-400
Oct 2, 2017 07:30AM Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia
Aug 25, 2017 08:02AM Sangamo Biosciences (SGMO), Pfizer (PFE) Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525
Aug 25, 2017 08:00AM Sangamo And Pfizer Announce First Patient Receives Treatment In Phase 1/2 Clinical Trial Evaluating SB-525 Investigational Gene Therapy For Hemophilia A
Jun 7, 2017 07:33AM Sangamo Biosciences (SGMO) & Pfizer (PFE) Granted Orphan Medicinal Product Designation from European Medicines Agency for SB-525 Investigational Hemophilia A Gene Therapy
Jun 7, 2017 07:30AM Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency
May 10, 2017 04:03PM Sangamo Biosciences (SGMO), Pfizer (PFE) Enter Pact on Hemophilia A Gene Therapy
May 10, 2017 04:01PM Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy
Jun 4, 2015 09:27AM Pre-Open Stock Movers 06/04: (BRLI) (AVEO) (FIVE) Higher; (MCP) (DRWI) (OPK) Lower (more...)
Jun 3, 2015 05:58PM After-Hours Stock Movers 06/03: (FIVE) (FEYE) (EYES) Higher; (DRWI) (SGMO) (BLUE) Lower (more...)
Feb 4, 2014 03:14PM Trading Radar for 02/05: Disney (DIS), Time Warner (TWX), Humana (HUM), Green Mountain (GMCR), Pandora (P) Report
View More Recent Stories